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Metastasis is the leading cause of death in patients with advanced mela-
noma, yet the somatic alterations that aid tumour cell dissemination and
colonisation are poorly understood. Here, we deploy comparative genomics
to identify and validate clinically relevant drivers of melanoma metastasis.
To do this, we identified a set of 976 genes whose expression level was
associated with a poor outcome in patients from two large melanoma
cohorts. Next, we characterised the genomes and transcriptomes of mouse
melanoma cell lines defined as weakly metastatic, and their highly meta-
static derivatives. By comparing expression data between species, we identi-
fied lunatic fringe (LFNG), among 28 genes whose expression level is
predictive of poor prognosis and whose altered expression is associated
with a prometastatic phenotype in mouse melanoma cells. CRISPR/Cas9-
mediated knockout of Lfng dramatically enhanced the capability of weakly
metastatic melanoma cells to metastasise in vivo, a phenotype that could be
rescued with the Lfng cDNA. Notably, genomic alterations disrupting
LFNG are found exclusively in human metastatic melanomas sequenced as
part of The Cancer Genome Atlas. Using comparative genomics, we show
that LFNG expression plays a functional role in regulating melanoma
metastasis.
1. Introduction
Melanoma is an aggressive cancer that develops from
the pigment-producing cells of the skin. In melanoma,
as in other cancers, metastasis accounts for the major-
ity of the mortality of patients with advanced disease
(Chaffer and Weinberg, 2011; Damsky et al., 2010).
This complex multistep process requires melanoma
cells to invade adjacent tissues, intravasate into the
lymphatics or blood vasculature, extravasate at distant
sites and ultimately colonise an organ or tissue. For
this to happen, melanoma cells must evade the
immune system and sculpt the host microenvironment
(Fidler, 2003).
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Several models of metastasis have been proposed
including those that describe monoclonal and poly-
clonal seeding. It is also clear that once a cell has
left the primary tumour, it may undergo further evo-
lution (Turajlic and Swanton, 2016). This complex
pattern of tumour cell dissemination and ongoing
evolution complicates the identification of the genetic
events that drive the metastatic process. Importantly,
transcriptome profiling of primary tumours has iden-
tified expression changes shown to be predictive of
metastasis (Paik et al., 2004; van de Vijver et al.,
2002), and alterations found in metastases have been
shown to be present in subclones in early primary
lesions (Wardwell-Ozgo et al., 2013). These data sup-
port the idea that a proportion of cells within pri-
mary tumours may evolve, acquire or have intrinsic
metastatic capabilities. Identifying those patients with
tumours at high risk of metastasising could help
identify individuals who may benefit from adjuvant
therapies or more regular screening (Eggermont,
2016).
In this study, we set out to identify clinically rele-
vant genes that confer enhanced metastatic capabilities
upon melanoma cells. To do this, we used compara-
tive functional genomics applied to gene expression
predictors of patient survival, combined with expres-
sion data from murine cell line models that have dif-
ferent capabilities to colonise the lung, a major site of
human melanoma metastasis. In this way, we identi-
fied a set of 28 genes associated with patient outcome
that were also differentially expressed when weakly
and highly metastatic mouse melanoma lines were
compared. We focused on lunatic fringe (LFNG) that
encodes for a glycosylating enzyme (O-fucosylpeptide
3-beta-N-acetylglucosaminyltransferase) that regulates
NOTCH signalling (Moloney et al., 2000), and show
an important role for this gene in controlling
melanoma metastasis.
2. Materials and methods
2.1. Survival analysis
Gene expression data generated using whole-genome
cDNA-mediated annealing, selection, ligation and
extension (DASL) arrays (Illumina Inc., San Diego,
CA, USA) from 217 (Leeds) (Nsengimana et al.,
2015) and 222 (Lund) (Jonsson et al., 2010) primary
melanomas (209 cutaneous, 13 mucosal) were
obtained. The Leeds data set (Leeds melanoma
cohort, N = 204, and chemotherapy study, N = 13)
was profiled on the human HT12.4 array, while the
Lund cohort was profiled on the earlier HT8.3
version. Quality control and normalisation of these
data sets has been published elsewhere (Jonsson
et al., 2010; Nsengimana et al., 2015). Briefly, the
HT8.3 version had a lower performance with only
7752 genes passing QC filters. The overlap between
this set and the Leeds data set using HT12.4 was
7584 genes. Survival benefit of each gene (log2 scale)
was assessed in a Cox proportional hazards model
using STATA v14.2 (STATACorp, Texas, USA) for
melanoma-specific survival (MSS) in the Leeds data
and overall survival (OS) using the data from Lund.
Analysis of the Leeds data set was adjusted for
patient age and sex. P-values were corrected for mul-
tiple testing (Benjamini–Hochberg false discovery rate,
FDR). Kaplan–Meier curves were plotted comparing
high to low gene expression relative to the median.
Functional gene annotation and enrichment analyses
of the genes that showed the same direction of asso-
ciation in both patient cohorts were performed using
DAVID (Huang et al., 2009).
2.2. Cell lines
B16-F0 and B16-F10 cell lines were purchased from
the American Type Culture Collection (ATCC), and
the B16-BL6, K1735-P and K1735-M2 lines were
obtained from the University of Texas M.D. Anderson
Cancer Centre. All cell lines were screened for the
presence of mycoplasma and other mouse pathogens
(Charles River Laboratories, Wilmington, MA, USA).
Cells were cultured at 37C in 5% CO2 in high glucose
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum, 29.2 mgmL1
L-glutamine, 10 000 unitsmL1 penicillin and
10 000 lgmL1 streptomycin.
2.3. Nucleic acid extraction and sequencing
For whole-genome sequencing, DNA was extracted
from cell pellets using the QIAGEN Puregene Core
Kit A. Paired-end 75-bp libraries were prepared and
sequenced using the Illumina HiSeq platform. Data
have been deposited in the European Nucleotide
Archive (ERP001691). RNA was extracted from cell
pellets using the QIAGEN RNeasy Mini Kit. Five
different vials were cultured and extracted per cell
line, to obtain five independent biological replicates
for each line. 1 lg of total RNA per sample was sub-
mitted for sequencing. Unstranded 75-bp paired-end
barcoded libraries were prepared with the standard
Illumina library preparation kit. RNA libraries were
sequenced on the Illumina Hiseq platform and the
data deposited in public databases (European
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Nucleotide Archive (ERP001690) and ArrayExpress
(E-ERAD-94)).
2.4. Whole-genome data processing and somatic
variant calling
Raw reads were mapped to the mouse reference gen-
ome (GRCm38p1) using bwa-mem (Li, 2013) v0.7.5
and PCR duplicates marked using Picard tools
MarkDuplicates v1.72 (http://broadinstitute.github.io/
picard). Single nucleotide variants (SNVs) and short
indels were called using Samtools mpileup (Li et al.,
2009) v0.1.19-58-g3d123 cd, and the resulting variants
were filtered using VCFTools (Danecek et al., 2011).
Variants with variant quality QUAL < 20, or number
of reads supporting the variant less than 5 (DP < 5) or
SNPGAP < 10, were discarded. Due to the absence of
a matched germline/normal sample from the exact
mouse from which the cell lines were generated, we
removed all variants reported by the mouse genomes
project (Keane et al., 2011) for the genetic back-
grounds of each cell line group. Similarly, variants
located within  50 bp of structural variants reported
by the mouse genomes project (Keane et al., 2011)
were also discarded. Finally, functional consequences
were predicted using ENSEMBL’s variant effect
predictor (v74) (McLaren et al., 2016).
2.5. Orthogonal validation of single nucleotide
variants using Sequenom
A total of 262 SNVs (116 for the K1735 lines and 146
for the B16 lines) were selected for orthogonal valida-
tion using the Sequenom platform. These variants were
randomly chosen using GATK’s ValidationSiteSelector
(v2.8-1-g932cd3a) from the set of variants that were
identified to be present in all the cell lines from each
group. All assays using the Sequenom platform were
performed with three biological replicates of each line.
2.6. Somatic signature identification and
comparison
Somatic mutational signatures were identified for each
mouse cell line group using the filtered somatic single
nucleotide variants (above). Signatures were identified
using the non-negative matrix factorisation method
from the SomaticSignatures R package (Gehring et al.,
2015) (v 2.6.1). To compare these signatures to
those reported in COSMIC (http://cancer.sanger.ac.
uk/cancergenome/assets/signatures_probabilities.txt),
we calculated cosine similarities as previously reported
(Alexandrov et al., 2015).
2.7. Copy number calling
Copy number alterations were identified using Con-
trol-FREEC (Boeva et al., 2011) v6.7 with 50-Kb win-
dows. Due to the lack of a matched normal for each
cell line, CNVs were called relative to parental cell
lines (B16-F0 and K1735-P); somatic CNVs for the
B16-BL6 line were called using the BAM file for
B16-F10.
2.8. Identification of differentially expressed
genes
Raw paired-end reads were aligned to the mouse refer-
ence genome (GRCm38p1) using the splice-aware
aligner Tophat2 (Kim et al., 2013) guided by
ENSEMBL mouse annotation (v73). Subsequently, the
number of uniquely mapped read pairs that were
aligned to each gene within the annotation with a
mapping quality > 10 were counted using htseq-count
(Anders et al., 2015). Raw counts were normalised by
calculating the fragments per kilobase per million
(FPKM) values for each gene for each replicate. As a
‘fit for use’ quality control, blind pairwise comparisons
across all the RNA-Seq samples were performed by
calculating the Pearson’s correlation coefficient based
on the FPKM values of all protein-coding genes of the
25 sequenced samples. This information was used to
group the samples using unsupervised hierarchical
clustering using the package gplots in R (Gregory
et al., 2013). To identify differentially expressed genes,
all of the four possible paired comparisons between
cell lines and their more metastatic derivatives were
made (B16-F10 vs B16-F0, B16-BL6 vs B16-F10, B16-
BL6 vs B16-F0 and K1735-M2 vs K1735-P) using
DESeq2 (Love et al., 2014). Once dispersion estimates
and normalised counts were calculated, genes with
mean normalised counts < 10 were filtered out and
P-values were re-adjusted using the Benjamini–Hoch-
berg correction for multiple testing. All genes with
P < 0.01 and a log2(foldchange) ≤2 or ≥ 2 were con-
sidered as differentially expressed.
2.9. Mouse–human orthologue identification
To identify the human orthologues of mouse genes,
the Compara module from the ENSEMBL Perl API
was used (Herrero et al., 2016). In cases where a
mouse gene had multiple orthologues in humans, the
gene with the highest percentage of identity when com-
paring the human and mouse proteins was selected.
Genes that had an ortholog classification of ‘many2-
many’ were not considered for further analysis.
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2.10. Randomisation test to identify the expected
number by chance of differentially expressed
mouse genes overlapping and concordant with
the list of genes associated with poor survival in
melanoma patients
Two independent randomisation tests were performed
using two different sample sizes 1290 or 388. A total of
1000 samples with randomly selected mouse genes (out
of the 15 412 genes with normalised fragment counts
> = 10 expressed by B16-F0 or B16-BL6) of each sam-
ple size were generated. Genes were selected without
replacement. For each randomly selected gene, a ran-
dom direction of expression was assigned with the same
probability as the one observed in the mouse data:
underexpressed (0.4621429) or overexpressed
(0.5378571). Then, each random sample was compared
to the list of human genes associated with poor outcome
with an FDR < 0.1 in our combined patient survival
analysis, to identify the number of overlapping and con-
cordant genes. Finally using the distribution of the num-
ber of overlapping and concordant genes across the
1000 samples, we calculated the probability of obtaining
a number of overlapping genes or more as the one
observed in the mouse cell line/human data comparison.
2.11. Cas9 gRNA selection
To select suitable gRNAs, we identified sequences in
the exons of candidate genes in the ENSEMBL v71
annotation of the GRCm38 mouse reference genome
( 05-NNNNNNNNNNNNNNNNNNNNNGG-3 0).
For each sequence, possible off-targets were identified
using Cas-Offinder (Bae et al., 2014). We then used
biomaRt (Durinck et al., 2009) to identify all possible
off-targets with up to three mismatches whose
expected cutting site overlapped an exon. Targeting
sequences with zero exonic off-targets with up to three
mismatches were selected. See Table S7.
2.12. Lfng disruption using a single gRNA (g2d1
clone generation)
Oligos with the Lfng gRNA sequence (Sigma-Aldrich
Corp, St. Louis, MO, USA) were cloned into the vector
PX459 (Addgene #48139) following the Zhang labora-
tory protocol (Ran et al., 2013). Plasmids were vali-
dated by Sanger sequencing using a U6 oligo (Table S7).
To obtain stable transfectants, the region containing
the U6 promoter, gRNA, gRNA scaffold and the
CBh-hSpCsn1-PURO-PolyA was excised and cloned
into the PiggyBac plasmid PB713B-1 to make
PX459_Lfng_g2_gRNA-PB713B-1 (Fig. S12B). B16-F0
cells (6 9 105) were cotransfected with 0.5 lg pCMV-
PiggyBac PBase (System Biosciences) and 5 lg of either
PX459_Lfng_g2_gRNA-PB713B-1 plasmid (to generate
Lfng-targeted cells) or empty PB713B-1 plasmid (to gen-
erate ‘control’ cells) using Fugene HD (Promega Cor-
poration, Madison, WI, USA). Twenty-four hours later,
5 lg puromycin was added to the medium and after
7 days individual colonies were isolated. Sequences
amplified from the Lfng locus were analysed with TIDE
(Brinkman et al., 2014) to identify clones with disrup-
tive mutations. Clone ‘g2d1’, carrying a homozygous 1-
bp insertion in Lfng, and clone ‘ca4’ (from the control
plate) were selected for further analysis.
2.13. Lfng disruption using two gRNAs (L1 clone
generation)
Oligos with the Lfng targeting sequences (Sigma-Aldrich
Corp) were cloned into the PiggyBac gRNA expressing
vector, Piggy_gRNAScaffold_BLASTO (Fig. S12B), fol-
lowing the Zhang’s laboratory protocol (Ran et al.,
2013). Plasmids carrying gRNA sequences were validated
by Sanger sequencing using a U6 oligo (Table S7). To
target Lfng using two different gRNA sequences (gRNAs
Lfng_g2 and Lfng_g3; Table S7), we first generated a
Cas9 stably expressing B16-F0 cell line by cotransfecting
6 9 105 B16-F0 cells with 5 lg of pPB-LR5.1-EF1a-pur-
o2ACas9 (Koike-Yusa et al., 2014) and 0.5 lg pCMV-
piggyBac. From this experiment, we cloned a single cell
line and cotransfected 6 9 105 cells with 2.5 lg of Piggy_
gRNAscaffold_Lfng_g2 and 2.5 lg of Piggy_gRNA
scaffold_Lfng_g3 (Fig. S12B), or LMDJ-Piggy_gRNAs-
caffold to generate a control cell line. Twenty-four hours
later, 10 lg blasticidin was added to the medium, and
after 7 days, individual colonies were isolated and
assessed for targeting of Lfng by PCR. Clone ‘L1’, carry-
ing a 4.8-kb deletion encompassing exons 1–4 of Lfng,
and clones ‘C1’ and ‘C2’ (from the control plate) were
selected for further analysis.
2.14. Lfng cDNA rescue experiments
To confirm that the metastasis phenotypes we observed
were due to the disruption of Lfng, we used plasmid
rescue in the L1 cell line using the vector PB533A-2 car-
rying a flag-tagged full-length Lfng cDNA (synthesised
by GeneArt) to generate the cell line L1-Lfng. L1-PB
cells carrying the empty vector were used as a control.
2.15. Assessment of Lfng expression in cell lines
by quantitative RT-PCR
For the comparison of Lfng expression levels between
cell lines, RNA was extracted from 1 9 106 cells using
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the RNAeasy mini Kit (QIAgen, Manchester, UK)
and cDNA was prepared using the SuperScript VILO
Master Mix (Thermo) according to the manufacturers’
instructions. RT-qPCR was performed using the Taq-
Man Fast Advanced Master Mix. Lfng
(Mm01201988_m1) and B2m (Mm00437762_m1)
assays were used for these studies. Reactions were per-
formed in quadruplicate using the StepOnePlus system
(Thermo Fischer Scientific, Waltham, MA, USA), and
analysis was performed using the DDCt method (Sch-
mittgen and Livak, 2008).
2.16. Western blotting
Western blotting was performed using standard
approaches. Anti-vinculin (clone V284) and anti-Flag
(clone M2) antibodies were used (Sigma-Aldrich Corp).
2.17. In vivo experimental metastasis assays
The experimental metastasis assay was performed as
described previously (van der Weyden et al., 2017). For
testing of the K1735-P and K1735-M2 cell lines, 1 9 105
cells were tail-vein-dosed into six- to eight-week-old wild-
type C3H/HeJ mice. After 10 days, mice were humanely
sacrificed and their lungs were collected into 10% neutral
buffered formalin and then processed for histopathologi-
cal analysis. For testing of the B16-F0, B16-F10, and
B16-BL6 cell lines, 0.75 9 105 cells were tail-vein-dosed
into six- to eight-week-old wild-type C57BL6/NTac mice
and their pulmonary metastatic burden was determined
7 days later by macroscopic counting. For testing the
Lfng-targeted g2d1 cells (and respective ca4 control cells),
4 9 105 cells were tail-vein-dosed, and for testing the
Lfng-targeted L1 cells (and respective C1/C2 control
cells), 5 9 105 cells were tail-vein-dosed; both into six- to
eight-week-old wild-type C57BL/6NTac mice. cDNA res-
cue experiments, using the cell line L1-Lfng and the con-
trol L1-PB, were performed using 4 9 105 cells. The
pulmonary metastatic burden was determined 10 days
postdosing by macroscopic counting. In all cases, sex-
matched mice were used. The care and use of all mice in
this study was in accordance with the Animals (Scientific
Procedures) Act 1986 Amendment Regulations 2012, and
all procedures were performed under a UK Home Office
Project licence (PPL 80/2562). All mice were housed in
individually ventilated cages (Techniplast GM500) receiv-
ing 60 air changes per hour, in a specific pathogen-free
environment with ad libitum access to autoclaved water
and food (Mouse Breeders Diet, Laboratory Diets, 5021-
3). Cages were filled with aspen bedding substrate, with a
nestlet and fun tunnel for environmental enrichment.
There was a 12-h light/dark cycle with no twilight period
with a temperature of 21 °C  2 °C and a humidity of
55%  10%. Throughout the experiment, the welfare of
the mice was monitored with daily visual checks.
2.18. Whole exome sequencing of the L1 cell line
DNA from L1 cells was exome-sequenced using Agilent
mouse whole exome baits. A 75-bp paired-end library
was prepared and sequenced on the Illumina HiSeq2500
platform. Data were analysed as above and are avail-
able in the European Nucleotide Archive (ERP015062).
3. Results
3.1. mRNA expression predictors of prognosis in
primary melanoma
Both tumour depth (Breslow thickness) and ulceration
are established predictors of melanoma metastasis
(Nsengimana et al., 2015), but the underlying mecha-
nisms that drive metastasis are unknown. We first set
out to identify genes whose expression levels were
associated with poor outcome. To do this, we analysed
the expression profiles of primary melanomas from
two previously published studies from Leeds (the
Leeds Melanoma Cohort and chemotherapy studies,
n = 217) and from the Lund Melanoma Research
Group (n = 222) (Jonsson et al., 2010; Nsengimana
et al., 2015). Demographic information for these
cohorts is provided in Table S1. Tumours from both
cohorts have been analysed using Illumina DASL
arrays such that the expression of 7584 genes may be
assessed. For the Leeds cohort, melanoma-specific sur-
vival (MSS) data were available, whereas overall survi-
val (OS) was recorded for the Lund cohort. Survival
analyses stratifying by gene expression were performed
using the Cox proportional hazards model. In this
way, we identified 976 genes whose expression levels
were significantly associated with patient outcome in
both cohorts (FDR < 0.1; Fig. 1A, Table S2). Of these
genes, 78.17% (763/976) showed the same direction of
association in both cohorts. These genes included
SKP2 (Chen et al., 2011), TOP2A (Song et al., 2013),
SOX4 (Jafarnejad et al., 2010), MAP2 (Soltani et al.,
2005) and CTLA4 (Hannani et al., 2015), all of which
have been associated with patient outcome in mela-
noma. Gene enrichment analysis found that biological
processes including epidermis development, ker-
atinocyte differentiation and immune response were
overrepresented (FDR < 0.01; Table S3) – biological
processes previously reported to be important in the
development of melanoma metastasis (Bald et al.,
2014; Golan et al., 2015).
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3.2. Genomic characterisation of murine
melanoma cell lines with contrasting metastatic
capabilities
To facilitate comparative analyses, we selected five
mouse melanoma cell lines with different metastatic
capabilities: B16-F0, B16-F10 and B16-BL6 derived
from C57BL/6 mice and K1735-P and K1735-M2,
derived from the C3H strain (Fidler, 1970, 1973;
Kripke, 1979; Kripke et al., 1978). Prior to genomic
analysis, we validated the metastatic capabilities of these
lines in vivo using an experimental metastasis assay
(Fig. 1B–C). Consistent with previous reports (Poste
et al., 1980; Talmadge and Fidler, 1982), B16-BL6 cells
were highly metastatic when compared to B16-F10 or
B16-F0 cells and K1735-M2 cells were highly metastatic
when compared to K1735-P cells. Spectral karyotyping
of these cell lines showed high levels of polyploidy and
multiple chromosomal aberrations (Figs. S1-S2 and
Table S4). We sequenced each of these lines to 30-56x
whole-genome coverage, using the Illumina HiSeq plat-
form. To identify somatic mutations (SNVs), we
mapped these data to the reference C57BL/6J genome
(GRCm38) and filtered the calls using variants described
by the Mouse Genomes Project (Keane et al., 2011) and
for quality (as detailed in Fig. S3). The number of vari-
ants shared among the lines within the B16 and K1735
groups is shown in Fig. 1D. The B16 lines showed
higher numbers of somatic SNVs and short indels
(~ < 50 bp) than the K1735 lines, with an average of
267 566 and 243 913 SNV, respectively (Fig. S4). A
copy number analysis was also performed (Fig. S5 and
Table S5). To assess our variant calling, we randomly
selected 262 variants for validation by Sequenom geno-
typing (146 identified from the B16 cell lines and 116
from the K1735 lines), obtaining an overall validation
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Fig. 1. Patient sample and mouse cell line characteristics. (A) Scatter plot showing the log10-corrected P-values for the 7584 genes
analysed in both cohorts in association with melanoma-specific survival in the Leeds cohort (x-axis) and overall survival in the Lund cohort
(y-axis). (B-C) Experimental metastasis assay using (B) B16 cell lines and (C) K1735 cell lines in wild-type female mice (symbols representing
individual mice with horizontal bar at the mean  SD and statistics performed using a Mann–Whitney test; data shown are representative
of two independent experiments). (D) Venn diagrams showing the number of variants shared between the mouse melanoma cell lines.
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rate of 90.86% for the B16 lines and 76.72% for the
K1735 lines (Fig. S6). In B16 cell lines, the predominant
mutation type was T > G (Fig. 2A) and the predomi-
nant mutational signature was Mmus-S1 (Fig. 2B),
which shows highest similarity to human mutational sig-
nature, signature 17 (Alexandrov et al., 2013) (cosine
similarity 0.872) – a signature whose aetiology is cur-
rently unknown but has been observed in melanoma
tumours (http://cancer.sanger.ac.uk/cosmic/signatures).
In K1735 cell lines, the predominant mutational signa-
ture was Mmus-S2 (Fig. 2B), with similarity to the UV
light signature reported by COSMIC (signature 7;
cosine similarity 0.597), which is in keeping with the
genesis of these lines following the combined adminis-
tration of UV light and croton oil (Kripke, 1979; Kripke
et al., 1978; Talmadge and Fidler, 1982). Further char-
acterisation revealed that both K1735 cell lines carried a
homozygous activating mutation in Nras (p.G13D) and
deletion of the first exon of Cdkn2a (p19 gene), as previ-
ously reported (Melnikova et al., 2004) (Fig. S7), as well
as an unreported Trp53 mutation (p.T74P) in K1735-P
cells (Fig. 2C). B16 cell lines carried a deletion of the
entire Cdkn2a locus, as previously reported (Melnikova
et al., 2004) (Fig. S7), as well as an unreported heterozy-
gous missense mutation in Braf (p.C263R; predicted to
be deleterious by SIFT), a missense Trp53 mutation (p.
N125D) and a mutation in Pten (p.T131P; Fig. 2C).
Finally, we could observe that mutations in Rac1 and
Nf1 were only present in the more invasive derivative
lines. For instance, the Rac1 missense mutation
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(p.A59S) was present only in B16-F10 cells. Similarly,
the splice site variant (Chr11.79408779T>G) within Nf1,
was observed in B16-BL6 and K1735-M2.
3.3. Transcriptomic characterisation of murine
melanoma cell lines
We generated RNA-seq data from five biological repli-
cates for each of the five melanoma cell lines.We mapped
the reads against the GRCm38 mouse reference genome,
counted the number of read pairs and verified the correla-
tion among biological replicates (r > 0.95; Fig. S8). In an
effort to identify changes in RNA levels that associate
with higher metastatic capabilities, we identified all genes
that were differentially expressed between the parental
lines (B16-F0, K1735-P) and their more metastatic deriva-
tives (B16-F10, B16-BL6 and K1735-M2). To do this, we
performed all possible paired comparisons within each
group using DESeq2 (Love et al., 2014). Genes were clas-
sified as differentially expressed if their P-value, after mul-
tiple testing correction, was P-adj < 0.01, with an
expression change of fourfold or more. In this way, we
identified a total of 1430 genes that were differentially
expressed (Table S6). qPCR was performed on selected
genes for validation (Fig. S9). Notably, no genes were con-
sistently differentially expressed across the comparisons of
B16 and K1735 parental lines to their more metastatic
derivatives (Fig. 2D–E), suggesting that different mecha-
nisms confer metastatic potential in these cell lines series.
3.4. Identification of conserved putative
regulators of metastatic colonisation in
melanoma
To identify putative regulators of metastatic colonisation
in melanoma, we next took a comparative genomics
approach (Fig. 3A). We identified the human ortho-
logues for all 1430 differentially expressed genes identi-
fied from the mouse melanoma cell line comparisons. For
each mouse gene, we selected the orthologue with the
highest protein sequence identity between mouse and
humans. All paralogous genes were discarded. These cri-
teria retained 1290 of the 1430 differentially expressed
genes. We intersected these genes with the 7584 genes
analysed in both human cohorts, which left 338 genes; 61
of which were significantly predictive of survival in both
human cohorts (FDR < 0.1). Of these 61 genes, 28 genes
showed the same direction of expression change (up- or
downregulation) in relation to poor patient outcome and
cell line metastasis phenotype (Table 1, Fig. 3B). A sum-
mary of the gene numbers obtained through each stage
of our analysis is presented in Fig. S10. To assess the sta-
tistical significance of this result, we performed two
independent randomisation tests revealing that the prob-
ability of obtaining 28 concordant genes by chance when
intersecting a gene set with the human survival data was
P (x ≥ 28) = 0.024 (when n = 1290) and P (x ≥ 28) = 0
(when n = 388) (Fig. S11).
Of the above-mentioned 28 genes, only one was upreg-
ulated in poor outcome patients, specifically MID1.
Notably, 5 of 28 genes we identified have previously been
reported to affect melanoma metastasis: CD82, NDRG2,
RUNX3, CCL5 and HDC. For example, reports suggest
that CD82 expression in melanoma cells inhibits tumour
cell extravasation and lung metastasis formation in vivo
(Khanna et al., 2014); upregulation of CD82 predicted
better outcome in our analysis of two independent
cohorts (Table 1). In addition to this, the tumour sup-
pressor N-myc downstream-regulated gene 2 (NDRG2)
is known to restrict melanomagenesis by regulating Mitf
expression (Kim et al., 2008). Similarly, the tumour sup-
pressor RUNX3 has been shown to be downregulated in
metastatic melanoma lines when compared to primary
melanoma or healthy skin (Kitago et al., 2009), while
expression of the chemokine and leucocyte chemoattrac-
tant CCL5 in B16 cells strongly suppresses lung metasta-
sis (Aravindaram et al., 2009). Finally, the histidine
decarboxylase (HDC) gene encodes a protein whose func-
tion is to convert L-histidine to histamine. Histamine has
been shown to play an important role in immune cell
function (Hansson et al., 1999), and a histamine/IL-2
combination has been used to increase T-cell responses in
stage IV melanoma patients (Asemissen et al., 2005). In
addition to the five genes mentioned above, an additional
nine genes (CCBE1, GPX3, PTK2B, LSP1, DDX60,
PARP14, GABRE, JUP and MID1) have been associ-
ated with metastasis in other types of epithelial or solid
cancers (Aktary and Pasdar, 2013; Bachmann et al.,
2014; Hao et al., 2010; Jeltsch et al., 2014; Koral et al.,
2015; Yue et al., 2015; Zhang et al., 2014b).
Next, we ranked the 28 identified genes based on
their hazard ratios and overall patient survival, as well
as their P-values after multiple test correction
(Table 1). Based on these criteria, we selected the gene
LFNG for further analysis.
Lunatic fringe (LFNG) is a glycosylating enzyme that
post-translationally modifies Notch receptor proteins
(LeBon et al., 2014). LFNG-mediated glycosylation of
Notch receptors alters the binding affinity of Notch pro-
teins with their ligands and activation of Notch receptors
by delta-like ligands (Kakuda and Haltiwanger, 2017). In
our analyses, low RNA levels of LFNG were shown to be
associated with poor outcome in both patient cohorts
(Fig. 3C–D). Moreover, LFNG is prognostic for mela-
noma-specific survival independent of Breslow thickness.
Furthermore, B16-BL6 cells had decreased Lfng
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expression when compared to its B16-F0 parental line
(log2(foldchange) = 2.185773, P = 1.069061 9 106,
negative binomial Wald test with Benjamini–Hochberg
correction), which was confirmed by qPCR (Fig. S12A).
3.5. Lfng disruption enhances the lung
colonisation capabilities of CRISPR/Cas9-targeted
melanoma cells
To test the effect of Lfng disruption on the metastatic
capabilities of melanoma cells, we used CRISPR/Cas9
to target Lfng in order to determine whether this may
confer enhanced metastatic capabilities upon the weakly
metastatic B16-F0 cell line (Fig. S12B). We generated
two independently targeted Lfng null B16-F0 clones,
termed g2d1 and L1 (Fig. 4A–B). G2d1 cells carried a
single base insertion resulting in a frameshift loss-
of-function mutation (Fig. S13) and L1 cells carried a
4.8-kb deletion encompassing exons 1–4 which we veri-
fied by exome sequencing (Fig. S14). Additionally,
exome sequencing identified that L1 cells carried 413
variants (334 SNVs and 79 Indels) not present in B16-
F0 cells. Of these variants, 120 were missense, two were
nonsense (altering genes Aqp3 and Vmn2r115) and three
were frameshift mutations (affecting Cyp7b1, Olfr657,
and Vmn2r115).
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In an experimental metastasis assay, both g2d1
cells (Fig. 4C–D) and L1 cells (Fig. 4E–F) showed
significantly increased numbers of pulmonary metas-
tases when compared to control cells (transfected
with an empty guide vector). These results directly
demonstrate that Lfng loss enhances the metastatic
capabilities of B16-F0 cells. It was notable that com-
pared to clone g2d1, clone L1 reproducibly produced
numerous smaller lung foci. To further confirm the
role of Lfng in metastasis, we used a full-length Lfng
cDNA to rescue the metastatic phenotype of L1 cells
(Fig 4G–H).
3.6. Analysis of somatic LFNG mutations in
human melanomas
Using two large patient cohorts (Jonsson et al., 2010;
Nsengimana et al., 2015), we showed that reduced
expression of LFNG is associated with poor patient
outcome. We next evaluated the prevalence of inacti-
vating somatic LFNG mutations in The Cancer Gen-
ome Atlas (TCGA) cutaneous melanoma collection
(Cancer Genome Atlas Network, 2015) comparing pri-
mary vs metastatic melanoma. In this way, we identi-
fied five samples (5/481) with nonsilent mutations
(four missense and one nonsense), all of which were in
metastases. Due to short follow-up times reported for
melanoma primary tumours by TCGA, assessment of
the association between LFNG expression and survival
is not possible.
3.7. Analysis of NOTCH pathway gene expression
in B16-derived melanoma lines
To explore the role of LNFG in metastasis further, we
next used our cell line transcriptome sequence data to
examine the expression of Notch pathway components
(Fig. 5). We observed significant changes in Notch
pathway elements in B16-BL6 such as upregulation of
Notch2, Jag1, Hes1, Esr1 and Rbpj, as well as down-
regulation of Rfng and Dll3, when compared to the
B16-F0 line. This result is in keeping with a functional
role for Lfng expression in the metastatic phenotypes
observed.
Table 1. Candidate genes identified in this study. Genes identified to be associated with metastasis and poor patient prognosis. This table
shows gene expression on a continuous scale. The hazard ratios (HR) shown are per each additional unit of log2 gene expression.
Gene
Leeds cohort Melanoma-Specific Survival Lund cohort overall survival
Hazard Ratio 95% C.I. P-val FDR Hazard Ratio 95% C.I. P-val FDR
CD82 0.58415 0.48411, 0.70485 2.03E-08 0.00020 0.52520 0.37432, 0.73692 0.00019 0.00153
LFNG 0.60248 0.45858, 0.79153 0.00027 0.01102 0.52328 0.38240, 0.71605 5.18E-05 0.00055
PTK2B 0.64250 0.52325, 0.78893 2.41E-05 0.00364 0.47279 0.31916, 0.70039 0.00019 0.00148
CCL5 0.67761 0.56575, 0.81157 2.35E-05 0.00360 0.57686 0.41392, 0.80393 0.00116 0.00629
LSP1 0.68714 0.57354, 0.82325 4.71E-05 0.00497 0.48760 0.33130, 0.71764 0.00027 0.00201
DDX60 0.71537 0.59150, 0.86520 0.00056 0.01594 0.53727 0.34560, 0.83524 0.00578 0.02156
PARP14 0.71561 0.58722, 0.87208 0.00091 0.02035 0.57359 0.37679, 0.87319 0.00953 0.03145
TUBA4A 0.71722 0.60117, 0.85567 0.00022 0.01002 0.31663 0.23623, 0.42440 1.42E-14 4.79E-12
GPX3 0.71882 0.60071, 0.86016 0.00031 0.01170 0.26009 0.10878, 0.62186 0.00246 0.01130
NDUFA4L2 0.72297 0.60147, 0.86901 0.00055 0.01588 0.67309 0.50482, 0.89746 0.00700 0.02488
GABRE 0.72349 0.59532, 0.87925 0.00114 0.02295 0.42004 0.28150, 0.62674 2.16E-05 0.00028
BTBD6 0.72365 0.58391, 0.89682 0.00313 0.04005 0.47218 0.25171, 0.88574 0.01938 0.05445
ITM2A 0.72406 0.60252, 0.87011 0.00057 0.01613 0.35698 0.25098, 0.50776 1.00E-08 3.96E-07
HDC 0.73176 0.61012, 0.87764 0.00076 0.01881 0.63449 0.51806, 0.77708 1.09E-05 0.00016
ELF4 0.73257 0.61273, 0.87584 0.00064 0.01716 0.56910 0.38619, 0.83865 0.00438 0.01738
RIPK3 0.73743 0.62606, 0.86861 0.00027 0.01085 0.40256 0.30353, 0.53388 2.67E-10 1.57E-08
CCBE1 0.73817 0.59969, 0.90862 0.00418 0.04704 0.35930 0.14251, 0.90584 0.03004 0.07619
PON3 0.74237 0.61458, 0.89673 0.00200 0.03083 0.64187 0.53994, 0.76304 5.02E-07 1.23E-05
BOC 0.74269 0.61053, 0.90345 0.00292 0.03872 0.67546 0.50016, 0.91219 0.01048 0.03398
RUNX1T1 0.74951 0.61916, 0.90730 0.00310 0.03987 0.57779 0.40754, 0.81917 0.00207 0.00983
FILIP1L 0.76881 0.64177, 0.92100 0.00433 0.04808 0.49836 0.36807, 0.67478 6.67E-06 0.00011
NDRG2 0.77243 0.64328, 0.92751 0.00567 0.05603 0.56030 0.40811, 0.76923 0.00034 0.00241
TSPAN33 0.77331 0.65148, 0.91792 0.00329 0.04124 0.46715 0.24663, 0.88486 0.01953 0.05474
FAM110C 0.77589 0.64552, 0.93259 0.00686 0.06188 0.62169 0.44282, 0.87281 0.00603 0.02221
JUP 0.77882 0.65184, 0.93053 0.00591 0.05722 0.61515 0.51528, 0.73437 7.62E-08 2.36E-06
RUNX3 0.78039 0.64937, 0.93784 0.00818 0.06857 0.34593 0.21468, 0.55742 1.29E-05 0.00018
EGLN3 0.78592 0.64904, 0.95166 0.01361 0.09212 0.42935 0.31385, 0.58735 1.23E-07 3.61E-06
MID1 1.37339 1.09496, 1.72262 0.00606 0.05803 3.45380 2.09940, 5.68197 1.06E-06 2.28E-05
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4. Discussion
In this study, we combined expression data from two
cohorts of melanoma patients with the analysis of a
selection of mouse cell lines with different metastatic
capabilities to identify LFNG as a regulator of metas-
tasis. We validated these results using CRISPR gen-
ome editing to transform a weakly metastatic mouse
cell line to a highly metastatic line by the disruption of
Lfng. Although our focus here was LFNG, many of
the other genes we discovered in our analysis may also
regulate melanoma metastasis. For example, the
DEXD/H box helicase 60 (DDX60) gene, a known reg-
ulator of the antiviral response and a DNA-/RNA-
binding protein, has been reported to be associated
with the development and prognosis of squamous cell
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carcinoma (Fu et al., 2016). Similarly, PTK2B has
been reported to be involved in the CCR7-mediated
regulation of metastasis in squamous cell carcinoma
(Yue et al., 2015) and was found to be downregulated
in our study.
Notch signal transduction occurs when a Notch
ligand (Jag or delta-like) from a sender cell binds to a
Notch receptor on an adjacent receiver cell (Bray,
2016). This event triggers the proteolytic cleavage of
the Notch intracellular domain (NICD). Subsequently,
NICD migrates to the nucleus and binds RBP-JK to
transcribe target genes. Notch receptor–delta-like
ligand binding affinity is regulated by the fringe glyco-
sylating enzymes (LFNG, MFNG and RFNG)
(Kakuda and Haltiwanger, 2017). In this study, we
show that low RNA levels of LFNG predict worse
outcome in patients with melanoma. Further, we find
that Lfng is downregulated in B16-BL6 cells when
compared to parental B16-F0 cells. Lfng ablation in
B16-F0 cells using CRISPR enhanced the number of
pulmonary metastases in support of its role in regulat-
ing metastasis. Previous work in pancreatic cancer has
showed that deletion of Lfng in a KrasLSL-G12D mouse
model upregulates Notch3 and Hes1, accelerating cell
proliferation (Zhang et al., 2016). A role for LFNG in
breast and prostate cancer has also been reported (Xu
et al., 2012; Zhang et al., 2014a). In highly metastatic
B16-BL6 cells, we observed overexpression of the
notch effectors, Hes1 and Notch2 (Fig. 5) as well as
Rbpj, Jag1, Maml2 and Mitf, relative to B16-F0 cells.
Notably, delta-like ligand (Dll3), as well as the fringe
genes, Lfng and Rfng, were underexpressed (Fig. 5) in
comparison with the Jag ligands, Jag1 and Jag2. This
suggests that B16 cells are more suited to activate the
Notch signalling pathway via Jag ligands.
In summary, this study shows how a cross-species
approach provides a useful framework for the identifi-
cation of clinically relevant genes that play a role in
metastasis. Identifying genetic markers such as LNFG
is important as it helps to identify those patients at
greatest risk of disease spread and may help guide
their management.
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Additional Supporting Information may be found
online in the supporting information tab for this
article:
Fig. S1. Spectral Karyotyping of the B16 cell lines.
Spectral karyotype analysis of ten different metaphases
from (A) B16-F0, (B) B16-F10 and (C) B16-BL6 cells.
High levels of polyploidy, multiple chromosomal aber-
rations and at least one event of whole genome ampli-
fication can be observed.
Fig. S2. Spectral Karyotyping of the K1735 cell lines.
Spectral karyotype analysis of ten different metaphases
from (A) K1735-P and (B) K1735-M2. High levels of
polyploidy, multiple chromosomal aberrations and at
least one event of whole genome amplification can be
observed.
Fig. S3. Cell line somatic variant calling and filtering
strategy. Diagram showing the multiple steps followed
to call single nucleotide variants and short indels from
whole genome data of the murine lines in the absence
of a matched normal sample from the same mouse.
Fig. S4. Somatic variants in murine melanoma cell lines
(A) Total number of SNV and indel variants identified
in each cell line. (B) Mean number SNVs identified in
each mouse melanoma cell line genome. (C) Bar plot
showing the mutational spectra of base substitutions
identified in the lines according to the 96-substitution
type and genomic context classification.
Fig. S5. Variation in highly metastatic mouse cell lines.
(A) Circos plot showing from the innermost track;
somatic short indels and SNVs identified uniquely in
the B16-BL6 cell line genome, the CNVs identified in
the B16-BL6 cell line against the B16-F0 genome, and
the CNVs identified in the B16-F0. (B) Circos plot
showing from the innermost track somatic short
indels, SNVs identified uniquely in the K1735-M2 cell
line genome, the CNVs identified in the K1735-M2 cell
line against the K1735-P and the CNVs identified in
the K1735-P parental line against the C3H/HeN gen-
ome.
Fig. S6. Orthogonal validation of SNVs identified in
the murine melanoma lines. A total of 262 variants
were tested; 146 from the B16 cell line group and 116
from the K1735 lines; using three biological replicates
per cell line. (A) Bar plot showing the proportion of
SNVs that were validated using the Sequenom technol-
ogy across three different replicates per cell line. (B)
Box and whisker plot showing the proportion of vali-
dated SNVs per cell line across the three replicates,
whiskers represent the upper and lower quartiles and
solid thick line represents the mean.
Fig. S7. Cdkn2a genomic deletions. (A) Screenshot
from the integrated genomics viewer showing the cov-
erage of the Cdkn2a locus, from top to bottom, on
the C57BL/6 genome data from (Keane et al., 2011),
the B16-F0, B16-F10 and B16-BL6 cell line genomes.
(B) Screenshot from the integrated genomics viewer
showing the coverage of the Cdkn2a locus, from top
to bottom, on the C3H/HeJ genome data from
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(Keane et al., 2011), the K1735-P and K1735-M2 cell
line genomes.
Fig. S8. Hierarchical clustering of the murine cell line
RNA-seq data. Heat map showing the hierarchical
clustering of different biological replicates sequenced
based on the Pearson correlation coefficient obtained
from all log2(TPM + 1) values across all the protein
coding genes. The two groups of cell lines can be
clearly observed.
Fig. S9. Analysis of differentially expressed genes.
Venn diagram showing the (A) overexpressed and (B)
under-expressed genes selected for qPCR validation.
(C-F) Gene expression levels with DDCT value being
relative to the respective parental line.
Fig. S10. Summary of genes assessed to identify regula-
tors of metastatic colonisation by comparative geno-
mics. Flow chart showing the number of genes obtained
throughout the different stages of our analysis to iden-
tify regulators of metastatic colonisation in melanoma.
Fig. S11. Number of overlapping and concordant genes
on random simulated samples. The null distribution of
overlapping genes observed across 1000 samples in a set
of randomisation tests with sample sizes of (A)
n = 1290, (B) n = 388. The dashed red line shows the
number of genes observed in our main analysis. The
probability of obtaining the same number of overlap-
ping genes as the ones observed in the real data is
shown.
Fig. S12. Validation of reduced Lfng expression in
B16-BL6 cells and plasmid constructs used to generate
Lfng-deficient B16-F0 cells. (A) Fold change in expres-
sion of Lfng in B16-BL6 cells against B16-F0 cells as
measured by qPCR, whiskers shows the standard error
and P-value was calculated using two tailed t test from
3 biological replicates. (B) Schematics of the different
plasmids used.
Fig. S13. Lfng targeting and validation of g2d1 clone.
(A) Diagram showing the targeting location of the
gRNA (Lfng_g2) used in the single targeting experi-
ment. (B) Expression analysis of g2d1 by quantitative
RT-PCR. Fold change in expression of Lfng in g2d1
cells against control cells as measured by qPCR, whis-
kers shows the standard error and P-value was calcu-
lated using two tailed t test from 3 biological
replicates. This frameshift mutation, although disrupt-
ing the gene, appears to cause an upregulation of Lfng
mRNA expression although the expression difference
is not statistically significant. (C) Pairwise alignment
using CLUSTALX 2.1 between mouse Lfng protein
(from Transcript ENSMUST00000031555) and the
resulting predicted protein in clone (g2d1) mutated
Lfng alleles. The single base insertion at the Lfng locus
causes a frameshift that introduces a stop codon 36
amino acids downstream of the mutation site.
Fig. S14. Lfng targeting and validation of L1 clone.
(A) Diagram showing the targeting location of the
gRNAs (Lfng_g2 and Lfng_g3) used in the double tar-
geting experiment. (B) Fold change in expression of
Lfng in L1 cells against control cells as measured by
quantitative RT-PCR, whiskers show the standard
error and P-value was calculated using two tailed t test
from 3 biological replicates. IGV screenshot showing
mapped reads from the whole exome sequencing data
generated from the Lfng KO clone (L1). Forward
reads are shown in blue and reverse reads are shown
in pink. Mismatched bases in comparison with the ref-
erence genome are highlighted above the read. The
position of the targeting sites for gRNAs (C) Lfng_g2
gRNA and (D) Lfng_g3 gRNA are highlighted with a
red box.
Table S1. Patient cohort demographic information.
Demographic information for the two patient cohorts
analysed where available.
Table S2. Predictors of patient outcome in both mela-
noma patient cohorts. Gene name, hazard ratios, con-
fidence intervals, P-value and corrected P-values for
all the genes with a P-val < 0.1 after applying the
FDR correction.
Table S3. Survival predictors gene set functional anno-
tation enrichment. Results of the functional annotation
enrichment analysis performed with DAVID with the
list of gene expression predictors of outcome.
Table S4. Summary of chromosomal aberrations iden-
tified by spectral karyotyping of the murine melanoma
cell lines. Summary of chromosomal aberrations
detected by spectral karyotyping in the different mouse
melanoma cell lines.
Table S5. Summary of Copy Number Variants identi-
fied on the mouse melanoma cell line genomes. Copy
number variants (CNV) calls identified in the cell line
genomes for the parental lines (B16-F0 and K1735-P).
Somatic CNVs are reported for the metastatic lines
(B16-F10, B16-BL6 and K1735-M2).
Table S6. Differentially Expressed genes identified
across the comparisons of all the murine melanoma
cell lines. Information on the 1430 genes that were dif-
ferentially expressed throughout all the comparisons.
Table S7. Oligos and gRNA sequences.
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